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doi:10.1016/j.jfma.2011.11.006Background/Purpose: In the past few years, many new subtypes in hepatitis C virus (HCV)
genotype 6 have been identified. The aim of this study was to modify the multiplex real-
time polymerase chain reaction (RT-PCR) protocol and use it to determine the HCV subtypes
of a group of Taiwanese injection drug users (IDUs).
Methods: We used 76 serum specimens collected in northern Taiwan in 2008. Multiplex RT-PCR
was used for HCV subtyping among those serum samples having anti-HCV antibodies. Twenty
cases were randomly selected for comparison with subtyping results from Inno-LiPa II tests
and phylogenetic tree analysis using NS5B sequences.
Results: Multiplex RT-PCR assays showed that 60.5% (46/76) of IDUs had single HCV infection.
Three out of 76 (3.9%) had double HCV infection (1b/6a, 2a/2b and 2b/6a). Besides this, 27.6%
(21/76) had no HCV signal. One IDU had subtype 6n and two had subtype 6w infection. Inno-
LiPa II tests misclassified all 6n and 6w cases as 1b subtype.
Conclusion: Our modified multiplex RT-PCR protocol can be used to support molecular epide-
miological studies and laboratory diagnoses of different HCV subtypes including genotype 6.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.tion and Research Center, National Yang-Ming University, No. 155, Li-Nong Street, Section 2, Taipei,
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The hepatitis C virus (HCV) is a positive single-stranded RNA
virus transmitted by blood-to-blood contact. Its gene
contains approximately 9400 nucleotides. Persistent HCV
infection is common among most HCV-infected patients and
chronic hepatitis results in cirrhosis of the liver and hepa-
tocellular carcinomas. The standard HCV typing approach
uses core/E1, NS5B or other genetic sequences. HCV is oneTable 1 The primer set and subtype fragment for multiplex re
multiplex PCR primer pair
core-first PCR
LF / SC2
LF:50-GGCCTTGTGGTACTG
SC2:50-GAG(AC)GG(GT)AT(
core-second PCR
mix 1 Subtype 1b
LF:50-GGCCTTGTGGTACTG
G1b:50-CCTGCCCTCGGGTT
Subtype 2a
LF:50-GGCCTTGTGGTACTG
S2a:50-AACACTAACCGTCG
Subtype 2a
LF:50-GGCCTTGTGGTACTG
G2a:50-CACGTGGCTGGGAT
Subtype 2b
LF:50-GGCCTTGTGGTACTG
G2b:50-GGCCCCAATTAGGA
Subtype 6w
LF:50-GGCCTTGTGGTACTG
6w:50-CCCGGGTTGCCCCCA
mix 2 Subtype 1a
LF:50-GGCCTTGTGGTACTG
G1a:50-GGATAGGCTGACGT
Subtype 4 or
subtype 6a
LF:50-GGCCTTGTGGTACTG
G4:50-CCCGGGAACTTAACG
Subtype 6a
LF:50-GGCCTTGTGGTACTG
G6a:50-GGTCATTGGGGCCC
Subtype 6 n
LF:50-GGCCTTGTGGTACTG
6 n:5-CCAGTGCCGGCCCGT
mix 3 Subtype 3a
LF:50-GGCCTTGTGGTACTG
G3a:50-GCCCAGGACCGGCC
Subtype 3b
LF:50-GGCCTTGTGGTACTG
G3b:50-CGCTCGGAAGTCTT
Subtype 5a
LF:50-GGCCTTGTGGTACTG
G5a:50-GAACCTCGGGGGG
Subtype 4
LF:50-GGCCTTGTGGTACTG
4r:50-GATCATTTGGGCCCCof several viral genes that are limited to specific geographic
regions and/or ethnic groups, thus supporting their use in
epidemiological research.1 Efforts to type the HCV gene
have resulted in the identification of six primary types and
multiple subtypes.2 HCV genotype 1a or 1b patients are
prone to more severe cases of liver disease and lower
response rates to interferon therapy compared to genotype
2a or 2b patients.3 Accordingly, HCV genotype testing is
required to determine the duration of interferon-basedal-time polymerase chain reaction.
Fragment used for
subtyping, np (length)
277-758 (482 bp)
CCTGA-30
AG)TACCCCATGAG(AG)TCGGC-30
277-563 (287 bp)
CCTGA-30
GGCTA(AG)-30
277-468 (192 bp)
CCTGA-30
CCCACAA-30
277-519 (243 bp)
CCTGA-30
CGCTCC-30
277-666 (390 bp)
CCTGA-30
CGAGAC-30
277-581 (305 bp)
CCTGA-30
GGTACG-30
277-537 (261 bp)
CCTGA-30
CTACCT-30
277-428 (152 bp)
CCTGA-30
TCCAT-30
277-675 (399 bp)
CCTGA-30
CAATGT-30
277-570 (294 bp)
CCTGA-30
T GGCT-30
277-571 (295 bp)
CCTGA-30
TTCGCT-30
277-505 (229 bp)
CCTGA-30
ACGTAC-30
277-649 (373 bp)
CCTGA-30
AGAGCAA-30
277-675 (399 bp)
CCTGA-30
AAGAC-30
Figure 1 Typical electrophoresis patterns for PCR products
among various HCV genotypes, as determined by our proposed
typing system. HCV genotype-specific product sizes in mixes 1,
2 and 3. Mix 1:egenotype 1b in lanes 3 and 4 (287 bp), geno-
type 2a in lanes 5 and 6 (243 bp), genotype 2b in lanes 7 and 8
(390 bp), and genotype 6w in lanes 15 and 16 (305 bp). Mix 2:
genotype 1a in lanes 1 and 2 (261 bp), genotype 6a in lanes 11
and 12 (399 bp) and genotype 6n in lanes 13 and14 (294 bp).
Mix3: genotype 3a in lanes 9 and 10 (295 bp).
764 Y.-M. Lee et al.therapies and the potential for positive responses.4,5 In this
regard, a number of HCV genotyping systems have been
developed. Nakao et al and McOmish et al have used
restriction fragment-length polymorphisms to identify HCV
genotypes6,7 and Okamoto et al and Chayama et al have
established genotype-specific primers for use with poly-
merase chain reaction (PCR).8,9
In the past we have used multiplex real-time (RT)-PCR
methods with HCV core genes for epidemiological studies
involving Taiwanese injecting drug users (IUDs).10 We found
that primers designed for HCV subtype 4 occasionally react
with some subtype 6a viral sequences, resulting in incorrect
identification problems. Furthermore, we discovered a new
6n subtype, and determined that the 6w subtype is rare in
Taiwan. Our motivation for the present study was to
develop a more accurate multiplex RT-PCR method for
identifying 6a, 6n and 6w subtypes. We used serum samples
from a group of Taiwanese IDUs for evaluation purposes,
and used Inno-LiPa tests and sequence analyses to evaluate
the accuracy of our results. Our ultimate goal was to create
a simple genotyping method for clinical applications and
epidemiological research.
Materials and methods
Participants and serologic assays
In 2008, we collected serum specimens from 48 HIV-1-
positive and 28 HIV-1-negative IDUs at the Sindian Drug User
Treatment Center in northern Taiwan. Specimens were
stored at 80C until used. Each participant signed
a consent form. All specimens were tested using third-
generation immunological enzyme HCV antibodies accord-
ing to the manufacturer’s instructions (Abbott Laborato-
ries, Chicago, USA).
Modified multiplex RT-PCR protocol
Our proposed genotyping system is a modification of the
protocol given in an article by Ohno et al,11 with two new
primers designed for the HCV 6n and 6w subtypes. We
observed that an antisense primer 4 reacted with HCV
subtype 6a isolates, and therefore labeled it as HCV type 4-
specific antisense primer 4r. All anti-HCV-positive samples
were tested using multiplex RT-PCR methods. Viral RNA was
extracted from 140 ml aliquots of serum using QIAamp
RNA extraction kits (Qiagen, Hilden, Germany). HCV-
complementary DNA was synthesized and amplified using
random primers (Promega, Canada). The first round RT-PCR
primer pairs were Sc2 and LF. Second round PCR was per-
formed in three separate reaction tubes with different
primer groups (see Table 1). This procedure can be used to
test for HCV subtypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, 6a, 6n
and 6w. Typical electrophoresis patterns for PCR products
among various HCV genotypes were showed in Fig. 1.
Inno-LiPa II tests
To evaluate multiplex RT-PCR analysis sensitivity and
specificity, 20 serum specimens were selected (includingsubtypes 1a, 1b, 2a, 2b, 3a, 3b, 6a, 6n and 6w) for second-
generation Inno-LiPa II tests (Innogenetics, Ghent, Belgium)
and sequence analysis. The specimens were from 18 IDUs
with single hepatitis C infections and two with multiple
infections. Tests were performed according to the manu-
facturer’s instructions.
Core and NS5B HCV sequencing
Core region phylogenetic analyses were performed using
methods described by Ohno et al.11 For NS5B analyses,
A hepatitis C genotyping protocol 765RT-PCR products were used for additional nested PCR
amplification with TaKaRa Ex TaqTM (TaKaRa Bio Inc.,
Otsu, Japan). The first round PCR primer pair was forward
primer NS5B-F1 (50-AACCACATCCACTCCGTGTGG-30) and
reverse primer NS5B-R1 (50-GGTCTTTACCGCCCAGTTGAA
GAG-30). The second round pair was forward primer
NS5B-F1 and reverse primer BS5B-SR2 (50-TACCTGGTCA
TAGCCTCCGTGAAG-30). As part of the PCR reaction, 2 ml of
complementary DNA was amplified for 40 cycles as follows:
20 cycles of denaturing at 94C for 1 minute, annealing at
45C for 1 minute, and extension at 72C for 1 minute,
followed by 20 cycles at 94C for 1 minute, 60C for
1 minute, and 72C for 1 minute. For the second PCR
round, 0.5 ml of first-round PCR product was amplified for
30 cycles of denaturing at 94C for 1 minute, followed by
annealing at 62C for 45 seconds, and extension at 72C for
1 minute.
Phylogenetic analysis
HCV genotype/subtype sequence alignments were deter-
mined using BioEdit 3.7 (Abbott, Carlsbad, CA, USA), with
sequences from the Los Alamos database used as a refer-
ence group (www.ncbi.nlm.nih.gov/). Neighbor-joining
phylogenetic trees were constructed using Kimura’s
two-parameter distance matrix (1000 bootstrap replica-
tions). MEGA 3.1 (MEGA, Tempe, AZ, USA) and PHYLIP 3.6
(University of Washington, USA) were used to construct
neighbor-joining trees and to verify taxa topologies
in maximum-likelihood trees, respectively.12,13 The
sequence for HCV strain H77 (accession number AF009606)
was used as a reference. We used the 8000-8604 (605 nt)
segment from the NS5B region for phylogenetic analysis
(Fig. 1).Table 2 Distribution of HCV genotypes in the injecting drug us
Characteristic HIV-1(þ)/IDUs HIV
(n Z 48) (
No. (%) No.
Anti-HCV Ab
Negative 0 (0)
Positive 48 (100)
Single-infection n Z 32 (66.7) n Z
1a 6 (12.5)
1b 6 (12.5)
2b 2 (4.2)
3a 4 (8.3)
3b 1 (2.1)
6a 12 (25.0)
6n 1 (2.1)
6w 0 (0)
Double-infection n Z 2 (4.2) n
1b/6a 1 (2.1)
2a/2b 0 (0)
2b/6a 1 (2.1)
No signal n Z 14 (29.2) nResults
Multiplex RT-PCR genotyping
The positive anti-HCV antibody rate was significantly
higher in HIV-1-positive IDUs than in HIV-1-negative IDUs
(100% vs. 78.6%, p Z 0.002). According to our multiplex
RT-PCR results, exactly two-thirds (32/48) of the HIV-1-
positive IDUs were infected with a single hepatitis C
virus typedprimarily the 6a genotype (12/48, 25%), fol-
lowed by 1a and 1b (6/48 or 12.5% each). Two participants
(4.2%) were identified as having double HCV infections.
Among the HIV-1-negative IDUs, exactly one-half (14/28)
were infected with a single HCV typedprimarily 6a, fol-
lowed by 1a (4/28, 14.3%); only one participant (3.6%) was
identified as having a double infection. No statistically
significant differences were noted for any distributions
between the two groups. Two HIV-1-negative IDUs were
infected with the 6w subtype. No HCV signals were found in
29.2% of the HIV-1-positive and 25% of the HIV-1-negative
IDUs (see Table 2).Determining HCV genotype by sequence analysis
According to results from more than 50% of our NS5B gene
sequence analyses specimens, the use of auxiliary deter-
minations from subtype 4r primers increased the accuracy
of 6a strain identification. Furthermore, the phylogenetic
trees produced by our proposed multiplex RT-PCR and
NS5B gene sequencing methods were 100% identical.
Subtype 6n and 6w strains identified by multiplex RT-PCR
genotyping assays were confirmed by sequence analysis
(see Fig. 2).ers group.
-1(-)/IDUs Total p
n Z 28) (n Z 76)
(%) No. (%)
0.002
6 (21.4) 6 (7.9)
22 (78.6) 70 (92.1)
14 (50.0) n Z 46 (60.5) 0.485
4 (14.3) 10 (13.2)
2 (7.1) 8 (10.5)
1 (3.6) 3 (3.9)
1 (3.6) 5 (6.6)
0 (0) 1 (1.3)
4 (14.3) 16 (21.1)
0 (0) 1 (1.3)
2 (7.1) 2 (2.6)
Z 1 (3.6) n Z 3 (3.9) 0.223
0 (0) 1 (1.3)
1 (3.6) 1 (1.3)
0 (0) 1 (1.3)
Z 7 (25.0) n Z 21 (27.6)
Figure 2 Phylogenetic trees based on: (A) partial core region sequences corresponding to nt 338e581, using maximum-likelihood
methods; and (B) partial NS5B region sequences corresponding to nt 8000e8578 in neighbor-joining trees. The H77 genome
(Genbank accession number NC004102) was used as a reference. Key: C Z the strains found in this study; : Z 6 w strain
* Z indicated confidence limits of p < 0.01.
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Results from line probe hybridization assays based on NS5B
gene sequencing indicate 85% (17/20) correct genotype
determinations for the sequence analysis. Discrepancies
included one case of 6n misdiagnosed as 1b, two cases of
6w misdiagnosed as 1b, and five cases of 6a infections that
were actually combinations of 6a and genotype 2 (see
supplemental Fig. 1).Discussion
Our results indicate identical levels of sensitivity and
specificity between our proposed method and both gene
sequencing and phylogenetic tree analyses for detecting
single subtype reactions. Our proposed method was supe-
rior in terms of detecting double HCV subtype infections.
To evaluate their multiplex RT-PCR method, Ohno et al
used 607 samples collected in Japan, the US, Korea, Tai-
wan, China, Hong Kong, Australia, Egypt, Bangladesh and
South Africa. Their results from 539 samples (88.8%) wereconcordant with those from a multiplex RT-PCR system
reported by Okamoto et al.9 Moreover, the genotypes of the
23 (out of 68) samples with discordant results had been
determined by sequence analysis, which concurred with
Ohno et al’s genotyping systems. Zhou et al, however, re-
ported that some 1b subtypes were wrongly identified as 6a
and some 6a subtypes identified as 1b using Ohno et al’s
method.14
HCV subtypes 6a-w are mostly found in IDUs living along
major drug trafficking routes in Vietnam, Thailand, Hong
Kong and China; most likely the IDUs transmit the virus
via shared syringes. Between 2003 and 2005, Taiwan
experienced a surge in infection rates for subtypes 6a
(23.5%), 3a (20.2%) and 1a (29.2%).15 During that period,
researchers identified two new subtypes: 6n and 6w.
A 13.3% increase in individuals with multiple infections has
also been reported.10 Proper diagnosis of HCV subtypes in
Southeast Asia requires increased primer specificity. We
offer our method as a step toward achieving that goal.
In this study, we used data from a 2008 project involving
Taiwanese IDUs. Our proposed multiplex RT-PCR procedure
successfully identified two cases of the 6w subtype;
A hepatitis C genotyping protocol 767a clustering effect noted in our phylogenetic tree analysis
verified this 6w result. This subtype was found in the HIV-1-
negative IDU group. To validate the accuracy and reliability
of this modified genotyping protocol, we applied the new
protocol to test samples selected from the previous study.10
The results showed that all the 6n (five cases) and 6w (three
cases) subtypes could be determined correctly and the 28
misclassified subtype 4 cases could be correctly reclassified
to subtype 6a.
In our previous study, the serum samples collected from
2004 to 2005 showed that subtypes 1b (36.0%) and 6a (30.0%)
were the most common ones found in northern Taiwan. In
this study, we selected samples from 2008 from when
genotype 6a was the most common subtype. The difference
in subtypes seen between 2004 and 2008 may be caused by
the differences in samples time and needle-sharing behav-
iors observed in the IDUs. We therefore suggest that future
researchers focus on the 6w strain when considering issues
associated with hepatitis C diagnosis and treatment.
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